Higher throughput comet assay for genotoxicity studies

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43CA096390-01A1
Agency Tracking Number: CA096390
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
TREVIGEN, INC.
TREVIGEN, INC., 8405 HELGERMAN CT, GAITHERSBURG, MD, 20877
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 JANOS LUKA
 (301) 216-2800
 JLUKA@TREVIGEN.COM
Business Contact
 MICHAEL ELLIOT
Phone: (301) 216-2800
Email: MELLIOTT@TREVIGEN.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): The comet assay allows for the detection of DNA damage in any accessible cell population and a molecular definition of the DNA damage is possible with adaptation of the basic assay. Trevigen has developed a platform for the comet assay consisting of a specially treated glass support, promoting the adherence of agarose, with demarcated sample application areas. This phase I proposal describes the development and validation of a higher-throughput format for comet assay. The system will consist of a support with multisample application areas pretreated for direct sample application for use with standard microscope platforms and current data analysis packages. The prototype will be validated for both the standard and the modified comet assay. The long term objective is to provide a rapid, cheap, standardized, and validated assay for the monitoring of genotoxicity of drugs or other treatments. The assay can be applied to both cells in culture for assessment of drugs very early in the screening process, and to samples obtained from animal tissue for specific organ toxicity monitoring of drug metabolites.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government